KR20010013881A - 파네실 단백질 전이효소의 신규한 n-치환된 우레아 억제제 - Google Patents

파네실 단백질 전이효소의 신규한 n-치환된 우레아 억제제 Download PDF

Info

Publication number
KR20010013881A
KR20010013881A KR1019997011903A KR19997011903A KR20010013881A KR 20010013881 A KR20010013881 A KR 20010013881A KR 1019997011903 A KR1019997011903 A KR 1019997011903A KR 19997011903 A KR19997011903 A KR 19997011903A KR 20010013881 A KR20010013881 A KR 20010013881A
Authority
KR
South Korea
Prior art keywords
hydrogen
compound
alkyl
aryl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019997011903A
Other languages
English (en)
Korean (ko)
Inventor
레미스체브스키스테이시
말람즈앨런케이.
Original Assignee
둘락 노먼 씨.
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 둘락 노먼 씨., 쉐링 코포레이션 filed Critical 둘락 노먼 씨.
Publication of KR20010013881A publication Critical patent/KR20010013881A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1019997011903A 1997-06-17 1998-06-15 파네실 단백질 전이효소의 신규한 n-치환된 우레아 억제제 Withdrawn KR20010013881A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87704997A 1997-06-17 1997-06-17
US08/877,049 1997-06-17

Publications (1)

Publication Number Publication Date
KR20010013881A true KR20010013881A (ko) 2001-02-26

Family

ID=25369144

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997011903A Withdrawn KR20010013881A (ko) 1997-06-17 1998-06-15 파네실 단백질 전이효소의 신규한 n-치환된 우레아 억제제

Country Status (14)

Country Link
EP (1) EP0989979A1 (https=)
JP (1) JP2002506444A (https=)
KR (1) KR20010013881A (https=)
CN (1) CN1267291A (https=)
AR (1) AR013094A1 (https=)
AU (1) AU8253598A (https=)
CA (1) CA2293706C (https=)
CO (1) CO4940458A1 (https=)
HU (1) HUP0002954A3 (https=)
IL (1) IL133389A0 (https=)
NZ (1) NZ501571A (https=)
PE (1) PE82799A1 (https=)
WO (1) WO1998057948A1 (https=)
ZA (1) ZA985205B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
EP1322334A2 (en) * 2000-10-05 2003-07-02 George Q. Daley Methods of inducing cancer cell death and tumor regression
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
EP1695961A4 (en) * 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
CA2904393A1 (en) * 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質のインヒビター
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110869357A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 化合物及其用于治疗癌症的使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CN111960990A (zh) * 2020-07-23 2020-11-20 宿迁联盛科技股份有限公司 一种助剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
IL125062A (en) * 1995-12-22 2003-11-23 Schering Corp Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
JP2001500508A (ja) * 1996-09-13 2001-01-16 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの阻害に有用な置換ベンゾシクロヘプタピリジン誘導体
ES2234036T3 (es) * 1996-09-13 2005-06-16 Schering Corporation Compuestos utiles para inhibir la farnesil-protein-transferasa.

Also Published As

Publication number Publication date
HUP0002954A3 (en) 2002-11-28
AU8253598A (en) 1999-01-04
JP2002506444A (ja) 2002-02-26
PE82799A1 (es) 1999-08-26
NZ501571A (en) 2002-02-01
HUP0002954A2 (hu) 2001-06-28
ZA985205B (en) 1998-12-15
IL133389A0 (en) 2001-04-30
EP0989979A1 (en) 2000-04-05
CO4940458A1 (es) 2000-07-24
CN1267291A (zh) 2000-09-20
WO1998057948A1 (en) 1998-12-23
CA2293706C (en) 2008-11-18
CA2293706A1 (en) 1998-12-23
AR013094A1 (es) 2000-12-13

Similar Documents

Publication Publication Date Title
KR20010013881A (ko) 파네실 단백질 전이효소의 신규한 n-치환된 우레아 억제제
US6239140B1 (en) Compounds useful for inhibition of farnesyl protein transferase
US6699872B2 (en) N-substituted urea inhibitors of farnesyl-protein transferase
KR20000036120A (ko) 파르네실 단백질 트랜스퍼라제에 대한 트리사이클릭 저해제
JP2002504149A (ja) G−タンパク質機能の阻害および増殖性疾患の処置のために有用なカルボキシピペリジルアセトアミド三環式化合物(ファルネシルタンパク質トランスフェラーゼインヒビター)
JP3269636B2 (ja) ファルネシルタンパク質トランスフェラーゼインヒビターとして有用な三環式ケトアミド誘導体
JP3258342B2 (ja) ファルネシルタンパク質トランスフェラーゼインヒビターとして有用なベンゾ(5,6)シクロヘプタピリジン化合物
US6218401B1 (en) Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
EP0991644B1 (en) Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US6426352B1 (en) Sulfonamide inhibitors of farnesyl-protein transferase
KR20010013826A (ko) 신규한 파네실-단백질 트랜스퍼라제의 트리사이클릭설폰아미드 억제제
JP3153555B2 (ja) ファルネシルタンパク質トランスフェラーゼのインヒビターとして有用な新規三環式n―シアノイミン
EP0993460B1 (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
KR20010013829A (ko) 파르네실 단백질 전이효소 억제제로서의벤조(5,6)사이클로헵타(1,2-b)피리딘 유도체
US6689789B2 (en) Compounds useful for inhibition of farnesyl protein transferase
EP0991643B1 (en) Novel aminooxyamide tricyclic inhibitors of farnesylprotein transferase
EP0993454B1 (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
EP0927179B1 (en) Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
KR20010013945A (ko) 파르네실-단백질 트랜스퍼라제의 신규한 페닐-치환된트리사이클릭 억제제
MXPA99012069A (en) Novel n-substituted urea inhibitors of farnesyl-protein transferase
KR20010013953A (ko) 파네실 단백질 트랜스퍼라제의 억제에 유용한 화합물
HK1028238B (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
KR20000068550A (ko) 파르네실 단백질 전이효소의 억제에 유용한 화합물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19991216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid